tbuckley/cabot-search huggingface dataset:
Surgery
Authors: A. E. Baue
Journal: JAMA (1980)

In surgery the decade of the 1970s may be characterized best as a period of confirmation or reaffirmation of what was known—a consolidation of gains. Innovations, new procedures, and new techniques became established as accepted treatment. Certainly new approaches were developed and introduced during this period, but progress came not so much from the new as from doing better what already could be done. The innovations of the 1960s were solidified in the 1970s. What constitute advances in surgery? New operations? Technical adaptations? Advances made by surgeons? The results of surgical research (a subject in itself, difficult to define)? Under the rubric are included all of these positive steps that improve the care of patients with diseases that customarily require operative therapy. Thus, progress in surgery may be a new operation, a better diagnostic approach, a better method of support for injured or postoperative patients, or elimination of the need
Efficacy and safety of anlotinib combined with TACE among patients with intermediate and advanced-stage hepatocellular carcinoma (HCC).
Authors: Lin Zheng, Hailiang Li, Chenyang Guo, Hongtao Hu, Fangkun Li
Journal: Journal of Clinical Oncology (2022)

454 Background: Given that the onset of hepatocellular carcinoma (HCC) remained insidious, HCC was usually diagnosed of intermediate and advaned stage and surgical resection was not available. Currently, TACE was considered as the standard of care for patients with intermediate and advaned stage HCC, which yielded a complete tumor necrosis rate of 10%̃20% and a median overall survival of 16-20 months. Interestingly, studies had demonstrated that TACE could result in up-regulation of VEGF expression and tumor angiogenesis, thus contributing to tumor recurrence or distant metastasis to some extent. As a novel oral multi-target antiangiogenic TKI, anlotinib could inhibit both tumor angiogenesis and tumor cell proliferation simultaneously. Therefore, anlotinib combined with TACE might play a synergistic action for patients with HCC. Consequently,this retrospective study aimed to investigate the efficacy and safety of anlotinib combined with TACE for patients with intermediate and advaned stage HCC. Methods: This single-center retrospective study involved 75 HCC patients with intermediate and advaned stage BCLC staging B or C and ECOG PS ≤ 2. Enrolled pts was treated with TACE plus anlotinib (12 mg, qd, 2 weeks on 1 week off) until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS), while the secondary outcomes included safety, objective response rate (ORR), disease control rate (DCR) and progression free survival (PFS) and safety. Both PFS and tumor response were based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Results: By the cutoff date of August, 2021, the median PFS of the 75 pts was 8.0 months (95%CI, 6.3-9.7). The median OS was not yet reached and the 6-month OS rate was 97.3%. In best overall response assessment, there were 13.3% CR (10/75), 45.3% PR (34/75), 34.7% SD (26/75) and 6.7% PD (5/75). Confirmed ORR and DCR was 58.7% (95% CI: 46.7%-69.9%) and 93.3% (95% CI: 85.1%-97.8%) respectively according to mRECIST. Only 5.3% (4/75) of pts had grade 3 treatment-related adverse events (TRAEs). No grade ≥ 4 TRAEs were observed. And the most common TRAEs were hypertension (20%), hand-foot skin reaction (8%), anorexia (6.7%) and diarrhea (6.6%). Conclusions: It was indicated that anlotinib combined with TACE for patients with intermediate and advaned stage HCC demonstrated promising anti-tumor efficacy and a favorable safety profile. The conclusion should be validated in prospective clinical trials subsequently.
Differences in Lymphocytic Diseases in the United States and Japan&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;
Authors: Robert W. Miller, M.D., Priscilla A. Gilman, M.D., Haruo Sugano, M.D.
Journal: JNCI Journal of the National Cancer Institute (1981)

Differences in Lymphocytic Diseases in the United States and Japan Robert W. Miller, M.D., Robert W. Miller, M.D. Clinical Epidemiology Branch Division of Cancer Cause and Prevention National Cancer Institute National Institutes of Health Public Health Service U.S. Department of Health and Human Services, Bethesda, Maryland 20205 Search for other works by this author on: Oxford Academic PubMed Google Scholar Priscilla A. Gilman, M.D., Priscilla A. Gilman, M.D. Clinical Epidemiology Branch Division of Cancer Cause and Prevention National Cancer Institute National Institutes of Health Public Health Service U.S. Department of Health and Human Services, Bethesda, Maryland 20205 Search for other works by this author on: Oxford Academic PubMed Google Scholar Haruo Sugano, M.D. Haruo Sugano, M.D. Cancer Institute Kami-Ikebukuro Toshima-ku, Tokyo 170, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 67, Issue 3, September 1981, Pages 739–740, https://doi.org/10.1093/jnci/67.3.739-a Published: 01 September 1981
Trends in Glycemic Control Among Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study
Authors: Faisal S. Malik, Katherine A. Sauder, Scott Isom, Beth A. Reboussin, Dana Dabelea, Jean M. Lawrence, Alissa Roberts, Elizabeth J. Mayer-Davis, Santica Marcovina, Lawrence Dolan, Daria Igudesman, Catherine Pihoker
Journal: Diabetes Care (2022)

To describe temporal trends and correlates of glycemic control in youth and young adults (YYA) with youth-onset diabetes.
Risk of Developing Type 2 Diabetes in Individuals With a Psychiatric Disorder: A Nationwide Register-Based Cohort Study
Authors: Nanna Lindekilde, Stine H. Scheuer, Lars J. Diaz, Katrine H. Rubin, Oleguer Plana-Ripoll, Jan Erik Henriksen, Mathias Lasgaard, Gregers S. Andersen, Frans Pouwer
Journal: Diabetes Care (2022)

OBJECTIVE Previous studies have investigated the incidence of type 2 diabetes in individuals with psychiatric disorders, but most studies have focused on a specific psychiatric disorder or a selected sample. More population-based studies are needed to determine these associations in representative samples. We therefore aimed to determine these associations in a nationwide, register-based dynamic cohort study. RESEARCH DESIGN AND METHODS We analyzed data from 5,005,612 adults living in Denmark between 1995 and 2018, without prior diabetes. We investigated 10 different categories of psychiatric disorders and a composite group with any psychiatric disorder. Individuals with a psychiatric disorder were compared with individuals without using multivariable-adjusted Poisson regression to estimate incidence rate ratios (IRR) of type 2 diabetes. We modeled age-specific incidence rates (IR) for individuals with and without the specific psychiatric disorder. All models were stratified by sex. RESULTS In total, 334,739 individuals developed type 2 diabetes during follow-up. For all investigated categories of psychiatric disorders, we found increased IR of type 2 diabetes for individuals with versus those without a psychiatric disorder (IRR: men, 1.47 [95% CI 1.45–1.50]; women, 1.65 [95% CI 1.62–1.68]). When we examined age-specific IR, the largest differences were found in the younger population (&amp;lt;50 years). CONCLUSIONS We found that the IR of type 2 diabetes was higher in individuals with a psychiatric disorder compared with individuals without a psychiatric disorder and particularly high in the younger people with a psychiatric disorder. New studies into the prevention and early detection of type 2 diabetes in these groups are warranted.
Error in Author Affiliation
Authors: Srishti Saha, Piyush Nathani, Arjun Gupta
Journal: JAMA Internal Medicine (2021)

Deepa Mohan, PhD; Andrew Mente, PhD; Mahshid Dehghan, PhD; Sumathy Rangarajan, MSc; Martin O’Donnell, MD, PhD; Weihong Hu, MSc; Gilles Dagenais, MD; Andreas Wielgosz, MD, PhD; Scott Lear, PhD; Li Wei, PhD; Rafael Diaz, MD; Alvaro Avezum, MD, PhD; Patricio Lopez-Jaramillo, MD, PhD; Fernando Lanas, MD, PhD; Sumathi Swaminathan, PhD; Manmeet Kaur, PhD; K. Vijayakumar, MD; Viswanathan Mohan, MD, DSc; Rajeev Gupta, PhD; Andrzej Szuba, MD, PhD; Romaina Iqbal, PhD; Rita Yusuf, PhD; Noushin Mohammadifard, PhD; Rasha Khatib, PhD; Khalid Yusoff, MBBS; Sadi Gulec, MD; Annika Rosengren, MD, PhD; Afzalhussein Yusufali, MD; Edelweiss Wentzel-Viljoen, PhD; Jephat Chifamba, DPhil; Antonio Dans, MD, MSc; Khalid F. Alhabib, MBBS; Karen Yeates, MD; Koon Teo, MBBCh, PhD; Hertzel C. Gerstein, MD, MSc; Salim Yusuf, MBBS, DPhil; PURE, ONTARGET, TRANSCEND, and ORIGIN investigators
Les abcès du poumon.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Pharmacology
Authors: Marcus M. Reidenberg
Journal: JAMA (1995)

One of the principal themes of clinical pharmacology is the scientific study of drug effects in humans. The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials: the Cardiac Arrhythmia Suppression Trial<sup>1</sup>reported in 1993 and the CONCORDE trial<sup>2</sup>reported in 1994. The Cardiac Arrhythmia Suppression Trial was designed to test the hypothesis that giving antiarrhythmic drugs that suppress premature ventricular beats would prolong survival in patients who recovered from myocardial infarctions. The patients were randomized to receive placebo or one of three antiarrhythmic drugs. The patients receiving active drugs had a higher 1-year mortality than those receiving placebo, and the trial was stopped.<sup>1</sup>The investigators concluded that suppressing asymptomatic ventricular premature beats with these antiarrhythmic drugs was not beneficial and appeared to be harmful. This was clearly contrary to the conventional wisdom that assumed that any intervention
BBS volume 19 issue 4 Cover and Back matter
Authors: Graeme Taylor, R Bagby, James Parker, Suniya Luthar, Jacob Burack, Dante Cicchetti, John Weisz
Journal: Behavioral and Brain Sciences (1996)

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Efficacy and safety of treatment of latrogenic femoral artery pseudoaneurysm percutaneously by biodegradable collagen Karim Hamraoui, Sjef M. P. G. Ernst, Thijs H. W. Plokker, Johannes C. Kelder, Jurri�n M. ten Berg, Els R. M. Marques, Maarten-Jan Suttorp, Wybren Jaarsma. St Antonius Hospital, Nieuwegein, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Gallium containing bioactive materials: A review of anticancer, antibacterial, and osteogenic properties
Authors: Fatih Kurtuldu, Nurshen Mutlu, Aldo R. Boccaccini, Dušan Galusek
Journal: Bioactive Materials (2022)

The incorporation of gallium into bioactive materials has been reported to enhance osteogenesis, to influence blood clotting, and to induce anti-cancer and anti-bacterial activity. Gallium-doped biomaterials prepared by various techniques include melt-derived and sol-gel-derived bioactive glasses, calcium phosphate bioceramics, metals and coatings. In this review, we summarize the recently reported developments in antibacterial, anticancer, osteogenesis, and hemostasis properties of Ga-doped biomaterials and briefly outline the mechanisms leading to Ga biological effects. The key finding is that gallium addition to biomaterials has great potential for treating bone-related diseases since it can be efficiently transferred to the desired region at a controllable rate. Besides, it can be used as a potential substitute for antibiotics for the inhibition of infections during the initial and advanced phases of the wound healing process. Ga is also used as an anticancer agent due to the increased concentration of gallium around excessive cell proliferation (tumor) sites. Moreover, we highlight the possibility to design different therapeutic approaches aimed at increasing the efficiency of the use of gallium containing bioactive materials for multifunctional applications.
Succor
Authors: Ora Paltiel
Journal: Annals of Internal Medicine (2019)

On Being a Doctor16 July 2019SuccorOra Paltiel, MDCM, MScOra Paltiel, MDCM, MScHadassah-Hebrew University, Jerusalem, Israel (O.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-0313 Audio Reading - “Succor” Audio. Virginia Hood, MD, reads “Succor” by Ora Paltiel, MDCM, MSc Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail My visit to a charity institution in Gondar, Ethiopia, taught me two of life's lessons. The date of my visit coincidentally marked my beginnings as a mother. On that day 33 years earlier, my first child had been born and I joined the ranks of those who not only gave birth but also cared for children, placing their children's needs above their own and nurturing, fretting, and praying for their well-being. Mother Teresa had been one such “mother” to the poorest of the poor. With my visit to this institution, which was founded in her name, I learned the profundity ... Author, Article, and Disclosure InformationAffiliations: Hadassah-Hebrew University, Jerusalem, Israel (O.P.)Corresponding Author: Ora Paltiel, MDCM, MSc, Hadassah-Hebrew University, POB 12000, Jerusalem 91120101, Israel; e-mail, [email protected]org.il. PreviousarticleNextarticle Advertisement Audio Reading - “Succor” Audio. Virginia Hood, MD, reads “Succor” by Ora Paltiel, MDCM, MSc Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 16 July 2019Volume 171, Issue 2Page: 141KeywordsChildrenComaGlobal healthGlucoseHypoglycemiaInsulinPatientsSucroseTouchType 1 diabetes ePublished: 16 July 2019 Issue Published: 16 July 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
International Comments
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment
Authors: Quanjun Yang, Juan Hao, Mengyi Chi, Yaxian Wang, Jie Li, Jinlu Huang, Jianping Zhang, Mengqi Zhang, Jin Lu, Shumin Zhou, Ting Yuan, Zan Shen, Shuier Zheng, Cheng Guo
Journal: Molecular Therapy (2022)

The effect of immunotherapy is limited by oncometabolite D-2-hydroxyglutarate (D2HG). D2HGDH is an inducible enzyme that converts D2HG into the endogenous metabolite 2-oxoglutarate. We aimed to evaluate the impairment of CD8 T lymphocyte function in the high-D2HG environment and to explore the phenotypic features and anti-tumor effect of D2HGDH-modified CAR-T cells. D2HG treatment inhibited the expansion of human CD8 T lymphocytes and CAR-T cells, increased their glucose uptake, suppressed effector cytokine production, and decreased the central memory cell proportion. D2HGDH-modified CAR-T cells displayed distinct phenotypes, as D2HGDH knock-out (KO) CAR-T cells exhibited a significant decrease in central memory cell differentiation and intracellular cytokine production, while D2HGDH over-expression (OE) CAR-T cells showed predominant killing efficacy against NALM6 cancer cells in high-D2HG medium. In vivo xenograft experiments confirmed that D2HGDH-OE CAR-T cells decreased serum D2HG and improved the overall survival of mice bearing NALM6 cancer cells with mutation IDH1. Our findings demonstrated that the immunosuppressive effect of D2HG and distinct phenotype of D2HGDH modified CAR-T cells. D2HGDH-OE CAR-T cells can take advantage of the catabolism of D2HG to foster T cell expansion, function, and anti-tumor effectiveness. The effect of immunotherapy is limited by oncometabolite D-2-hydroxyglutarate (D2HG). D2HGDH is an inducible enzyme that converts D2HG into the endogenous metabolite 2-oxoglutarate. We aimed to evaluate the impairment of CD8 T lymphocyte function in the high-D2HG environment and to explore the phenotypic features and anti-tumor effect of D2HGDH-modified CAR-T cells. D2HG treatment inhibited the expansion of human CD8 T lymphocytes and CAR-T cells, increased their glucose uptake, suppressed effector cytokine production, and decreased the central memory cell proportion. D2HGDH-modified CAR-T cells displayed distinct phenotypes, as D2HGDH knock-out (KO) CAR-T cells exhibited a significant decrease in central memory cell differentiation and intracellular cytokine production, while D2HGDH over-expression (OE) CAR-T cells showed predominant killing efficacy against NALM6 cancer cells in high-D2HG medium. In vivo xenograft experiments confirmed that D2HGDH-OE CAR-T cells decreased serum D2HG and improved the overall survival of mice bearing NALM6 cancer cells with mutation IDH1. Our findings demonstrated that the immunosuppressive effect of D2HG and distinct phenotype of D2HGDH modified CAR-T cells. D2HGDH-OE CAR-T cells can take advantage of the catabolism of D2HG to foster T cell expansion, function, and anti-tumor effectiveness.
Marriages
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COVID-19 hindering progress against female genital mutilation
Authors: None The Lancet Public Health
Journal: The Lancet Public Health (2021)

Feb 6 marked the annual International Day of Zero Tolerance for Female Genital Mutilation (FGM)—a violation of girls' and women's health and human rights. It is estimated that more than 200 million women and girls have been subjected to FGM; in addition, each year, an estimated 3 million girls are at risk. FGM is an extreme form of violence and discrimination against girls and women, reflecting deep-rooted gender inequality.
AIDS Policy: Two Divisive Issues
Authors: Ronald Bayer
Journal: JAMA (1993)

<h3>To the Editor.</h3> — As study director (J.S.) and panel member (R.B.) of the National Research Council (NRC) project on the social impact of acquired immunodeficiency syndrome (AIDS), we write to respond to a recent Commentary by Drs Rogers and Osborn.<sup>1</sup> The NRC report concluded that despite the enormous human suffering wrought by AIDS, the human immunodeficiency virus (HIV) epidemic has had minimal impact on some key institutions of American life. It noted that a "major reason for this limited response is the concentration of the epidemic in socially marginalized groups."<sup>2(p7)</sup> This conclusion provoked an outraged reaction by people who took offense at press accounts highlighting this passage. Many commentators responded before having a chance to read the 322-page report that focused on the impact of AIDS on a half-dozen select social institutions. We had hoped the second wave of responses to the report in professional journals would
Physical Diagnosis
Authors: Frederick L. Glauser
Journal: JAMA (1987)

<i>Physical Diagnosis</i>, 17th edition, by John W. Burnside and Thomas J. McGlynn is the continuation of a book first published by a Dr Cabot in 1900. The contents are logically arranged; the first four chapters give an overview of history taking, physical examination, and physician-patient interrelations. The remaining chapters cover the different organ systems, from skin to nervous system. Each of these chapters is subdivided into history, anatomy, examination, and common findings. Important points are stressed by placing them in heavy print in the text and using tables liberally. Illustrations consist of clear photographs and some excellent drawings. Overall, this is a "Dr Jekyll and Mr Hyde" textbook. The "Dr Jekyll," or good, aspects are the first four chapters in which the authors lucidly and in detail discuss clinical diagnosis, decision making, probability analysis, behavior and attitudes of patients and physicians, and the problem-oriented record. These chapters are excellent, particularly